LifeMD Inc

LifeMD Inc(LFMD)股票分析

$2.290

-0.150 (-6.53%)收盘时

Loading chart…
最高
2.490
开盘
2.460
成交量加权均价
2.33
成交量
597.21K
市值
279.29M
最低
2.205
成交额
1.39M
企业价值/息税折旧摊销前利润(TTM)
-3.54

LifeMD, Inc. is a patient-centric, direct-to-patient healthcare company. The Company is engaged in providing patients access to virtual medical care and pharmacy services. Its telehealth platform helps patients access licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis and sells over the counter (OTC) products. Its products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments of prescribed medications or products. The Company's men's brand, RexMD, offers access to virtual medical treatment for a variety of men's health needs, including erectile dysfunction, premature ejaculation and hair loss. Its vertically integrated care model combines technology, affiliated clinical services, pharmacy infrastructure, and artificial intelligence (AI)-enabled operational systems to deliver longitudinal care.

AI 分析 of LifeMD Inc (LFMD)

买入

LifeMD Inc appears to be a good buy right now due to its current price of $2.31, which is significantly below its 52-week high of $5.73, indicating potential for upside. The stock has a forward P/E ratio of 12.85, suggesting it may be undervalued compared to future earnings. Additionally, the RSI is at 55.54, indicating the stock is neither overbought nor oversold, which is a favorable technical indicator. However, the main risk is the company's net income, which has been negative, with a reported loss of $9.64 million in Q1 2026, highlighting ongoing financial challenges.

估值指标

LifeMD Inc(LFMD)当前预期市盈率为 12.85,5 年平均预期市盈率为 -15.58。

预期市盈率

合理
5 年均值 P/E
-15.58
当前P/E
12.85
高估
43.95
低估
-75.10

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
5.86
当前EV/EBITDA
-3.54
高估
18.37
低估
-6.64

预期市销率

低估
5 年均值 P/S
0.93
当前P/S
0.48
高估
1.37
低估
0.49

Alphio AI 对 LFMD 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%LFMD

$14.58

情景价格

基

基准

基准 · 50%LFMD

$13.42

情景价格

悲

悲观

悲观 · 25%LFMD

$9.37

情景价格

事件时间线

2026-11-05 (ET)

10:00:00

LifeMD Partners with Eli Lilly for Direct GLP-1 Drug Dispensing

2026-09-17 (ET)

12:00:00

H.C. Wainwright Gives LifeMD Buy Rating, Price Target $9

2026-08-05 (ET)

18:30:00

LifeMD Sees Q3 Adjusted EBITDA Loss of $1M to Gain of $2M

18:30:00

LifeMD Cuts FY26 Revenue Outlook to $6B Loss

资讯

LFMD 常见问题 —— 由 Alphio AI 解答

LifeMD, Inc. is a patient-centric, direct-to-patient healthcare company. The Company is engaged in providing patients access to virtual medical care and pharmacy services. Its telehealth platform helps patients access licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis and sells over the counter (OTC) products. Its products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments of prescribed medications or products. The Company's men's brand, RexMD, offers access to virtual medical treatment for a variety of men's health needs, including erectile dysfunction, premature ejaculation and hair loss. Its vertically integrated care model combines technology, affiliated clinical services, pharmacy infrastructure, and artificial intelligence (AI)-enabled operational systems to deliver longitudinal care. It operates in the Healthcare sector (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry).

LifeMD Inc appears to be a good buy right now due to its current price of $2.31, which is significantly below its 52-week high of $5.73, indicating potential for upside. The stock has a forward P/E ratio of 12.85, suggesting it may be undervalued compared to future earnings. Additionally, the RSI is at 55.54, indicating the stock is neither overbought nor oversold, which is a favorable technical indicator. However, the main risk is the company's net income, which has been negative, with a reported loss of $9.64 million in Q1 2026, highlighting ongoing financial challenges.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易